A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1. 1This trial specifically targets people with major depression who also have moderate-to-severe insomnia symptoms — does my particular combination of depression and sleep problems match what they're looking for in participants?
2. 2Since this is a Phase 3 trial, seltorexant has already been through earlier safety testing, but the open-label phase is still closely monitoring things like suicidality using the C-SSRS and withdrawal symptoms — what does that tell us about the remaining unknowns with this drug, and how would that be managed if I enrolled?
3. 3The open-label phase is tracking changes in body weight, BMI, and waist circumference as primary outcomes — is there anything about my current health that would make those kinds of changes especially risky for me?
4. 4The trial is measuring sexual functioning using the ASEX scale throughout the open-label phase, which suggests this could be a real side effect — how does seltorexant's potential impact on sexual function compare to the antidepressants I might otherwise take?
5. 5Given that standard antidepressant treatments already exist for major depression, would it make more sense for me to try an established therapy first, or is there a specific reason you think a trial like this one could be worth considering for my situation?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.